Wave Life Sciences Second Quarter 2025 Earnings: Misses Expectations

Simply Wall St · 08/01 12:08

Wave Life Sciences (NASDAQ:WVE) Second Quarter 2025 Results

Key Financial Results

  • Revenue: US$8.70m (down 56% from 2Q 2024).
  • Net loss: US$50.5m (loss widened by 53% from 2Q 2024).
  • US$0.31 loss per share (further deteriorated from US$0.25 loss in 2Q 2024).
earnings-and-revenue-growth
NasdaqGM:WVE Earnings and Revenue Growth August 1st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Wave Life Sciences Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 9.8%. Earnings per share (EPS) also missed analyst estimates by 6.2%.

Looking ahead, revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 3.5% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Wave Life Sciences has 3 warning signs (and 1 which is a bit concerning) we think you should know about.